Loading...
XNAS
PTIX
Market cap3mUSD
Dec 05, Last price  
1.67USD
1D
-0.60%
1Q
-46.98%
Name

Protagenic Therapeutics Inc

Chart & Performance

D1W1MN
XNAS:PTIX chart
P/E
P/S
EPS
Div Yield, %
Shrs. gr., 5y
13.82%
Rev. gr., 5y
%
Revenues
0k
00018,721,00036,982,000113,884,00069,089,00040,026,00085,00000000000000
Net income
-6m
L+10.49%
-7,900,000-2,234,000-94,470677,000-4,149,000-115,766,000-29,470,000-19,727,000-1,027,000-1,079,000-476,000-2,275,826-2,259,636-2,557,531-1,766,797-2,794,913-4,986,639-3,601,556-5,000,497-5,525,000
CFO
-4m
L+13.84%
1,870,000-842,000-44,000931,000-5,210,0004,355,000-3,015,000-11,250,000-324,000-790,000-378,000-1,140,319-1,380,089-1,071,188-487,990-1,348,779-2,798,614-1,993,814-3,703,776-4,216,517

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Protagenic Therapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound is PT00114, a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. The company is based in New York, New York.
IPO date
Dec 18, 1996
Employees
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT